Every Form 4 that Voyager Therapeutics, Inc. (VYGR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VYGR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VYGR filings page.
Voyager Therapeutics director George A. Scangos received a grant of stock options for 30,000 shares of common stock as director compensation. The options have an exercise price of $3.43 per share and expire on June 9, 2036.
According to the company’s 2025 Stock Incentive Plan, all 30,000 underlying shares vest upon the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, assuming he continues to serve as a director. After this grant, Scangos holds 30,000 stock options directly.
Voyager Therapeutics, Inc. director Catherine J. Mackey received a grant of stock options to acquire 30,000 shares of common stock. The options have an exercise price of $3.43 per share and expire on June 9, 2036.
According to the company’s 2025 Stock Incentive Plan and director compensation policy, all 30,000 underlying shares vest upon the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, as long as she continues serving as a director. Following this award, she holds 30,000 options directly from this grant.
Voyager Therapeutics, Inc. reported that director Steven Hyman received a grant of stock options to buy 30,000 shares of common stock at an exercise price of $3.43 per share. The award was made under the company’s 2025 Stock Incentive Plan as part of its director compensation policy.
All 30,000 underlying shares vest upon the earlier of one year from the grant date or the next annual meeting of stockholders, provided he continues to serve as a director. The filing does not show any option exercises or open-market share purchases or sales associated with this grant.
Voyager Therapeutics, Inc. director Nancy Vitale received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $3.43 per share and expire on June 9, 2036. All 30,000 underlying shares vest on the earlier of one year from the grant date or the next annual meeting of stockholders, subject to her continued service as a director. Following this grant, she holds options for 30,000 shares directly.
Voyager Therapeutics, Inc. director Michael J. Higgins received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of 3.43 per share and expire on June 9, 2036.
The award was issued under Voyager’s 2025 Stock Incentive Plan as part of its director compensation policy. All 30,000 underlying shares vest on the earlier of one year from the grant date or the next annual stockholder meeting, if he continues serving as a director.
Voyager Therapeutics director Jude Onyia received a grant of stock options covering 30,000 shares of common stock. The options have a $3.43 per share exercise price and expire on June 9, 2036, giving him the right to buy shares at that price in the future.
These options were issued under the company’s 2025 Stock Incentive Plan as part of its director compensation policy. All 30,000 underlying shares vest upon the earlier of one year from the grant date or the next annual stockholder meeting, subject to his continued board service.
Voyager Therapeutics director James A. Geraghty reported receiving a grant of stock options under the company’s 2025 Stock Incentive Plan. The award covers 30,000 options to buy common stock at an exercise price of $3.43 per share, expiring on June 9, 2036.
All 30,000 underlying shares vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, provided he continues serving as a director. After this grant, his reported derivative holdings from this award total 30,000 options.
Voyager Therapeutics director Grace Colon received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $3.43 per share and expire on June 9, 2036. They were granted under the company’s 2025 Stock Incentive Plan as part of its director compensation policy.
All 30,000 underlying shares vest upon the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, provided Colon continues to serve as a director through that date. This is a routine, compensation-related equity award rather than an open‑market stock purchase or sale.
Voyager Therapeutics director Glenn Pierce received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $3.43 per share and expire on June 9, 2036. All 30,000 underlying shares vest on the earlier of one year from the grant date or the next annual stockholders’ meeting, subject to his continued board service.
Voyager Therapeutics, Inc. President and CEO Alfred Sandrock reported an open-market sale of 11,511 shares of common stock at a weighted average price of $3.87 per share. The transaction occurred under a durable automatic sale instruction to cover tax withholding on restricted stock units that vested on April 1, 2026.
The filing notes the sale was not a discretionary trade by Sandrock. Following this sell-to-cover transaction, he directly holds 472,549 shares of Voyager Therapeutics common stock.
Shiferman Gregory L. reported acquisition or exercise transactions in this Form 4 filing.
Voyager Therapeutics, Inc. granted 50,000 restricted stock units (RSUs) to SVP and General Counsel Gregory L. Shiferman as equity compensation. Each RSU represents one share of common stock upon vesting.
The award was granted on April 1, 2026 under the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan. The RSUs vest over three years: one-third on the first anniversary of the grant date and one-third on each of the next two anniversaries, contingent on his continued service. After this grant, he holds 50,000 shares/RSUs directly.
Voyager Therapeutics COO & CBO Robin Swartz reported an automatic tax-related sale of 6,458 common shares. On February 24, 2026, shares were sold in an open-market transaction at a weighted average price of $3.77 per share.
The sale was executed under a durable automatic sale instruction adopted on May 12, 2025 to cover tax withholding obligations from restricted stock units that vested on February 21, 2026, and is described as non-discretionary. After this sale, Swartz directly held 199,738 Voyager Therapeutics shares.
Voyager Therapeutics, Inc. director and President & CEO Alfred Sandrock reported an open-market sale of common stock tied to tax withholding. He sold 14,197 shares of common stock at a weighted average price of $3.79 per share in transactions on February 24, 2026.
The sale was executed under a durable automatic sale instruction adopted on May 12, 2025 to satisfy tax withholding obligations arising from the vesting of restricted stock units on February 21, 2026, and is described as not a discretionary trade. Following these transactions, Sandrock directly holds 484,060 shares of Voyager Therapeutics common stock.
Voyager Therapeutics, Inc. Chief Financial Officer Nathan D. Jorgensen reported an open-market sale of 4,668 shares of common stock at a weighted average price of $3.77 per share. After this non-discretionary sell-to-cover tax transaction, he holds 151,416 shares directly.
Voyager Therapeutics’ Chief Scientific Officer, Carter Todd Alfred, reported an automatic sale of 4,174 shares of common stock at a weighted average price of $3.76 per share.
The shares were sold under a pre-set instruction to cover tax withholding tied to restricted stock units vesting on February 21, 2026, and he continues to hold 145,718 shares directly.
Voyager Therapeutics, Inc. executive Robin Swartz, the company’s COO & CBO, reported an open-market sale of 3,882 shares of common stock at a weighted average price of $3.44 per share on February 18, 2026. The sale was made under a pre-established durable automatic sale instruction adopted on May 12, 2025 to cover tax withholding obligations tied to restricted stock units that vested on February 17, 2026, and is described as non-discretionary. Following this transaction, Swartz directly owned 206,196 common shares of Voyager Therapeutics.
Voyager Therapeutics, Inc. Chief Scientific Officer Carter Todd Alfred reported an automatic open-market sale of 3,301 shares of common stock at a weighted average price of $3.44 per share. The shares were sold under a pre-established durable automatic sale instruction adopted on May 12, 2025 to cover tax withholding obligations arising from the vesting of restricted stock units on February 17, 2026, and are described as not being a discretionary trade. Following this transaction, Alfred directly holds 149,892 shares of Voyager Therapeutics common stock.
Voyager Therapeutics, Inc. President and CEO Alfred Sandrock reported an open-market sale of 11,732 shares of common stock of Voyager Therapeutics at a weighted average price of $3.41 per share. According to the disclosure, this transaction was executed under a durable automatic sale instruction adopted on May 12, 2025.
The shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units on February 17, 2026, and the filing states that the sale did not represent a discretionary trade by the reporting person. After this tax-related sale, Sandrock directly holds 498,257 shares of Voyager Therapeutics common stock.
Swartz Robin reported open-market sale transactions in a Form 4 filing for VYGR. The filing lists transactions totaling 4,569 shares at a weighted average price of $3.85 per share. Following the reported transactions, holdings were 210,078 shares.
Sandrock Alfred reported open-market sale transactions in a Form 4 filing for VYGR. The filing lists transactions totaling 12,192 shares at a weighted average price of $3.78 per share. Following the reported transactions, holdings were 509,989 shares.
Carter Todd Alfred reported open-market sale transactions in a Form 4 filing for VYGR. The filing lists transactions totaling 3,525 shares at a weighted average price of $3.85 per share. Following the reported transactions, holdings were 153,193 shares.
Voyager Therapeutics Chief Medical Officer receives new equity awards. On February 6, 2026, Toby Ferguson was granted 45,000 restricted stock units (RSUs) and a stock option for 210,000 shares of common stock at an exercise price of $3.68 per share.
The RSUs vest over three years, in three equal annual installments starting one year after the grant date, subject to continued service. The stock option vests over four years, with 1/48th of the shares vesting monthly after the first month, also conditioned on continued service. Following the RSU grant, Ferguson directly beneficially owns 183,914 shares of common stock.
Voyager Therapeutics Chief Scientific Officer equity awards: Todd Alfred Carter received 33,000 restricted stock units and a stock option for 154,000 shares of Voyager Therapeutics common stock on February 6, 2026. The RSUs vest over three years and the option, with a $3.68 exercise price, vests monthly over four years, both based on continued service.
Voyager Therapeutics COO & CBO Robin Swartz reported new equity awards in the company. On February 6, 2026, Swartz was granted 45,000 shares of common stock for no cash consideration, issuable under restricted stock units awarded pursuant to the 2025 Stock Incentive Plan. Following this grant, Swartz beneficially owned 214,647 shares of common stock directly.
On the same date, Swartz received a stock option for 210,000 shares of common stock with an exercise price of $3.68 per share, expiring on February 6, 2036. The RSUs vest over three years in annual installments, and the option vests monthly over four years, in each case conditioned on continued service.
Voyager Therapeutics, Inc. President and CEO Alfred Sandrock reported equity awards on February 6, 2026. He received 402,500 stock options with a $3.68 exercise price, expiring on February 6, 2036, vesting monthly over four years, subject to continued service.
He was also awarded 86,250 restricted stock units, vesting in three equal annual installments starting one year after the grant date, also subject to continued service. Following these awards, he beneficially owned 522,181 shares of common stock, including 5,000 shares acquired under the company’s employee stock purchase plan.
Voyager Therapeutics’ Chief Financial Officer Nathan D. Jorgensen reported new equity awards. He received 32,250 shares of common stock for no cash cost, issuable under restricted stock units that vest over three years starting on February 6, 2026, subject to continued service.
He was also granted a stock option to buy 150,500 shares at an exercise price of $3.68 per share. This option vests monthly over four years starting on February 6, 2026. After these grants, he directly beneficially owned 156,084 shares of common stock.
Voyager Therapeutics, Inc. reported that its SVP and General Counsel, Gregory L. Shiferman, received a grant of stock options for 100,000 shares of common stock on January 6, 2026. The options have an exercise price of $4.02 per share and were issued under the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan. The options vest over four years, with one quarter of the underlying shares vesting on the one-year anniversary of the grant date and the remaining shares vesting in equal monthly installments over the following three years, contingent on his continued employment. Following this grant, he holds 100,000 stock options directly.
Voyager Therapeutics, Inc. (VYGR) Chief Financial Officer Nathan D. Jorgensen reported the sale of 7,666 shares of common stock on 10/03/2025. The sales were executed under a pre-existing durable automatic sales instruction (a sell-to-cover election) tied to the vesting of restricted stock units, to satisfy tax withholding. The weighted-average price reported for the shares sold was $4.78, with individual trade prices ranging from $4.74 to $4.85. After the reported transaction, the reporting person beneficially owned 123,834 shares of common stock.